---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-253636"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:58:43.972148+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China

## Summary
- Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.
- Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.
- Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt.

## SEC filing metadata
- accession: 0001193125-25-253636
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/0001193125-25-253636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525253636/vor-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-253636
- JSON: https://secwatch.observer/filing/0001193125-25-253636.json
- Plain text: https://secwatch.observer/filing/0001193125-25-253636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.